PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage

View source ↗

Summary

The EMA’s PRAC recommends additional restrictions for Zinbryta (daclizumab) due to risks of serious liver injury, including potential life-threatening and fatal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Zinbryta (daclizumab high yield process)